文献速递心境障碍

普拉克索增效治疗难治性单相抑郁急性期:英国安慰剂对照双盲随机试验

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK.
PubMed 文献 · Lancet Psychiatry · 2025-06-29

普拉克索组因不良事件终止治疗更常见(20% vs 5%)。

要点

  • 普拉克索增效在12周时较安慰剂显著降低难治性抑郁症状评分。
  • 普拉克索组不良事件终止治疗20%,安慰剂组5%。

核心结论

  • 在难治性抑郁患者中,普拉克索增效抗抑郁治疗在12周时较安慰剂减少症状,但伴有一些不良事件。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机试验,在英国九家NHS信托机构进行,为期48周。
  • 主要分析基于意向治疗人群,共151例随机分配(普拉克索组75例,安慰剂组75例,1例随机后发现不符合条件)。

主要发现

  • 因不良事件终止试验治疗:普拉克索组15例(20%),安慰剂组4例(5%),不良事件包括恶心、头痛、睡眠障碍或嗜睡。

关键数值与推荐

  • 主要结局为基线至第12周QIDS-SR16总分变化。
  • 因不良事件终止治疗比例:普拉克索组20%,安慰剂组5%。

临床怎么用

  • 对于难治性单相抑郁,在持续抗抑郁药基础上加用普拉克索可能减少症状。
  • 使用普拉克索增效时需监测恶心、头痛、睡眠障碍或嗜睡等不良事件。

局限性

  • 原文未报告 ethnicity 数据。
  • 未来需直接比较普拉克索与现有治疗难治性抑郁的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: About 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression. METHODS: We did a multicentre, double-blind, placebo-controlled randomised trial in which adults with resistant major depressive disorder were randomly assigned (1:1; using an online randomisation system) to 48 weeks of pramipexole (titrated to 2·5 mg) or placebo added to their ongoing antidepressant medication. The study was conducted in nine National Health Service Trusts in England. Participants, investigators, and researchers involved in recruitment and assessment were masked to group allocation, and the central pharmacy team dispensing the medication was not masked. The primary outcome was change from baseline to week 12 in the total score of the 16-item Quick Inventory of Depressive Symptomology self-report version (QIDS-SR16). The primary analysis was performed on the intention-to-treat population that included all eligible, randomly assigned participants. People with lived experience were involved in the design, oversight, and interpretation of the study. The trial was registered with ISCTRN (ISRCTN84666271) and EudraCT (2019-001023-13) and is complete. FINDINGS: Between Feb 16 and May 29, 2024, 217 participants attended a screening visit, of whom 66 were excluded due to ineligibility. 151 participants were randomly assigned (75 to the pramipexole group and 75 to the placebo group, after one participant was found to be ineligible after randomisation). 84 (56%) participants were female and 66 (44%) were male and the mean age of participants was 44·9 years (SD 14·0). Ethnicity data were not available. The mean QIDS-SR16 total score at baseline was 16·4 (SD 3·4) in the pramipexole group and 16·2 (3·5) in the placebo group. The mean dose of pramipexole received at week 12 was 2·3 mg (SD 0·45). Adjusted mean decrease from baseline to week 12 of the QIDS-SR16 total score was 6·4 (SD 4·9) for the pramipexole group and 2·4 (4·0) for the placebo group; the mean difference between groups was -3·91 (95% CI -5·37 to -2·45; p<0·0001). Termination of trial treatment due to adverse events was more frequent in the pramipexole group (15 participants [20%]) than in the placebo group (four participants [5%]), with reported adverse events consistent with known side-effects of pramipexole, in particular nausea, headache, and sleep disturbance or somnolence. INTERPRETATION: In this trial involving participants with treatment-resistant depression, pramipexole augmentation of antidepressant treatment, at a target dose of 2·5 mg, demonstrated a reduction in symptoms relative to placebo at 12 weeks but was associated with some adverse effects. These results suggest that pramipexole is a clinically effective option for reducing symptoms in patients with treatment-resistant depression. Future trials directly comparing pramipexole with existing treatments for this disorder are needed. FUNDING: National Institute of Health and Care Research, Efficacy and Mechanism Evaluation Programme.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Browning M, Cowen PJ, Galal U, et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry. 2025. PMID: 40602411. doi:10.1016/S2215-0366(25)00194-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。